QQQ   443.86 (-0.22%)
AAPL   171.16 (-1.24%)
MSFT   419.91 (-0.36%)
META   486.24 (-1.54%)
GOOGL   150.73 (-0.09%)
AMZN   179.96 (+0.07%)
TSLA   177.36 (-1.37%)
NVDA   905.83 (+0.37%)
NIO   4.56 (-2.36%)
AMD   180.53 (+0.52%)
BABA   72.43 (+1.17%)
T   17.66 (+0.63%)
F   13.18 (+0.92%)
MU   117.65 (-1.25%)
CGC   9.71 (+1.68%)
GE   174.83 (-2.94%)
DIS   122.49 (+1.25%)
AMC   3.68 (-15.21%)
PFE   28.02 (+0.86%)
PYPL   67.09 (+0.78%)
XOM   115.96 (+0.86%)
QQQ   443.86 (-0.22%)
AAPL   171.16 (-1.24%)
MSFT   419.91 (-0.36%)
META   486.24 (-1.54%)
GOOGL   150.73 (-0.09%)
AMZN   179.96 (+0.07%)
TSLA   177.36 (-1.37%)
NVDA   905.83 (+0.37%)
NIO   4.56 (-2.36%)
AMD   180.53 (+0.52%)
BABA   72.43 (+1.17%)
T   17.66 (+0.63%)
F   13.18 (+0.92%)
MU   117.65 (-1.25%)
CGC   9.71 (+1.68%)
GE   174.83 (-2.94%)
DIS   122.49 (+1.25%)
AMC   3.68 (-15.21%)
PFE   28.02 (+0.86%)
PYPL   67.09 (+0.78%)
XOM   115.96 (+0.86%)
QQQ   443.86 (-0.22%)
AAPL   171.16 (-1.24%)
MSFT   419.91 (-0.36%)
META   486.24 (-1.54%)
GOOGL   150.73 (-0.09%)
AMZN   179.96 (+0.07%)
TSLA   177.36 (-1.37%)
NVDA   905.83 (+0.37%)
NIO   4.56 (-2.36%)
AMD   180.53 (+0.52%)
BABA   72.43 (+1.17%)
T   17.66 (+0.63%)
F   13.18 (+0.92%)
MU   117.65 (-1.25%)
CGC   9.71 (+1.68%)
GE   174.83 (-2.94%)
DIS   122.49 (+1.25%)
AMC   3.68 (-15.21%)
PFE   28.02 (+0.86%)
PYPL   67.09 (+0.78%)
XOM   115.96 (+0.86%)
QQQ   443.86 (-0.22%)
AAPL   171.16 (-1.24%)
MSFT   419.91 (-0.36%)
META   486.24 (-1.54%)
GOOGL   150.73 (-0.09%)
AMZN   179.96 (+0.07%)
TSLA   177.36 (-1.37%)
NVDA   905.83 (+0.37%)
NIO   4.56 (-2.36%)
AMD   180.53 (+0.52%)
BABA   72.43 (+1.17%)
T   17.66 (+0.63%)
F   13.18 (+0.92%)
MU   117.65 (-1.25%)
CGC   9.71 (+1.68%)
GE   174.83 (-2.94%)
DIS   122.49 (+1.25%)
AMC   3.68 (-15.21%)
PFE   28.02 (+0.86%)
PYPL   67.09 (+0.78%)
XOM   115.96 (+0.86%)
NASDAQ:VRTX

Vertex Pharmaceuticals (VRTX) Stock Price, News & Analysis

$419.10
+1.78 (+0.43%)
(As of 01:22 PM ET)
Today's Range
$415.06
$420.67
50-Day Range
$407.69
$446.08
52-Week Range
$310.90
$448.40
Volume
374,196 shs
Average Volume
1.31 million shs
Market Capitalization
$108.26 billion
P/E Ratio
30.17
Dividend Yield
N/A
Price Target
$417.27

Vertex Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Hold
2.41 Rating Score
Upside/​Downside
0.6% Downside
$417.27 Price Target
Short Interest
Healthy
1.60% of Float Sold Short
Dividend Strength
N/A
Sustainability
-3.12
Upright™ Environmental Score
News Sentiment
0.81mentions of Vertex Pharmaceuticals in the last 14 days
Based on 13 Articles This Week
Insider Trading
Selling Shares
$7.99 M Sold Last Quarter
Proj. Earnings Growth
8.96%
From $14.95 to $16.29 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.25 out of 5 stars

Medical Sector

160th out of 939 stocks

Pharmaceutical Preparations Industry

63rd out of 433 stocks

VRTX stock logo

About Vertex Pharmaceuticals Stock (NASDAQ:VRTX)

Vertex Pharmaceuticals Incorporated, an American biopharmaceutical company headquartered in Boston, Massachusetts, was founded in 1989 by Joshua Boger and Kevin J. Kinsella with a vision to revolutionize disease treatments through rational drug design. Their mission is to "transform the way serious diseases are treated," and they have made significant strides in achieving this goal. The company specializes in researching, developing, and commercializing innovative therapies for various medical conditions, primarily focusing on cystic fibrosis. Using cutting-edge science and technology, Vertex has become a leading player in the biotech industry, particularly in the field of precision medicine.

Vertex has overcome challenges and achieved milestones, chronicled in Barry Werth's book "The Billion-Dollar Molecule." Over the years, the company's research and development efforts have primarily targeted viral infections, inflammatory and autoimmune disorders, cancer, and other specialty diseases. Vertex's flagship products are dedicated to treating cystic fibrosis, a genetic condition affecting the respiratory and digestive systems. Notable among these are Kalydeco, the first FDA-approved drug addressing the underlying cause of cystic fibrosis for specific gene mutations, Orkambi, a combination drug for patients with the most common cystic fibrosis mutation (F508del), Symdeko, a dual combination treatment for certain gene mutations and Trikafta, a groundbreaking triple-combination therapy for cystic fibrosis.

The company's target market consists of patients suffering from serious diseases, especially those with cystic fibrosis and other genetic disorders. Vertex's therapies are designed to cater to specific gene mutations, offering personalized and precision medicine approaches. Key customers include patients with cystic fibrosis and their families, healthcare providers specializing in genetic diseases and health systems, and insurers providing access to these life-changing therapies. Vertex Pharmaceuticals has achieved significant financial growth in recent years, reflecting its successful drug development efforts. Impressive revenue metrics and robust earnings metrics indicate the company's ability to translate its research into profitable treatments efficiently. The company's strong profit margin metrics also showcase its effective financial management.

The positive financial performance has driven the company's stock price upwards, reflecting investor confidence in Vertex's ability to deliver innovative therapies and capitalize on unmet medical needs. The company's strong financials, expanding product pipeline, and contributions to cystic fibrosis treatment have justified its favorable valuation compared to industry peers. Vertex Pharmaceuticals' successful development and commercialization of Trikafta have been key drivers behind the company's positive valuation and investor sentiment. The drug's significant impact on patients and its potential for continued growth have attracted investors seeking exposure to the dynamic biopharmaceutical sector.

As Vertex explores gene-editing therapies in collaboration with CRISPR Therapeutics and Arbor Biotechnologies, investors view the company as a strategic player in addressing significant unmet medical needs. The company's commitment to research and development further solidifies investor confidence in its long-term prospects.

Vertex Pharmaceuticals has demonstrated resilient stock performance. Investors recognize the company's value as a pioneer in the biotech industry, with a focus on precision medicine and transformative therapies. The company's dedication to research and its successful commercialization of existing drugs underscores its strategic positioning in the market.

As Vertex continues to expand its product pipeline and explore new treatment avenues, investors remain optimistic about the company's growth potential. The company's innovative research collaborations, particularly in gene-editing therapies, are expected to drive further positive investor sentiment. In the broader industry, Vertex Pharmaceuticals is well-positioned relative to its peers. Its specialization in precision medicine and groundbreaking therapies for genetic diseases sets it apart, giving the company a competitive advantage. Vertex's successful track record and commitment to addressing unmet medical needs further reinforce its strong position in the market.

While Vertex Pharmaceuticals has achieved significant milestones, the company faces certain risks and challenges. Regulatory hurdles, competitive pressures, and the need for continued investment in research and development are potential factors that may impact its future growth. However, the company's risk management strategies and prudent financial management are designed to mitigate potential risks and position Vertex for continued success. As the company continues to innovate and expand its product portfolio, it is expected to maintain its strong position in the biopharmaceutical industry.

VRTX Stock Price History

VRTX Stock News Headlines

Geron Stock Doubles After Imetelstat Receives FDA Panel Approval (VRTX)
Geron stock is up more than 92% after the company's flagship blood cancer therapy received approval from an FDA advisory panel
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
3 Biopharma Stocks Predicted to Soar in Q2 2024
VRTX Mar 2024 335.000 put
Q4 2023 MaxCyte Inc Earnings Call
The Top 3 Biotech Stocks to Buy in March 2024
See More Headlines
Receive VRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vertex Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/05/2024
Today
3/28/2024
Next Earnings (Estimated)
5/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:VRTX
CUSIP
92532F10
Employees
5,400
Year Founded
1989

Price Target and Rating

Average Stock Price Target
$417.27
High Stock Price Target
$540.00
Low Stock Price Target
$325.00
Potential Upside/Downside
-0.4%
Consensus Rating
Hold
Rating Score (0-4)
2.41
Research Coverage
22 Analysts

Profitability

Net Income
$3.62 billion
Pretax Margin
44.38%

Debt

Sales & Book Value

Annual Sales
$9.87 billion
Cash Flow
$14.67 per share
Book Value
$68.22 per share

Miscellaneous

Free Float
257,275,000
Market Cap
$108.18 billion
Optionable
Optionable
Beta
0.35

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Should I Buy Vertex Pharmaceuticals Stock? VRTX Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Vertex Pharmaceuticals was last updated on Wednesday, March 27, 2024 at 11:16 PM.

Pros

Here are some ways that investors could benefit from investing in Vertex Pharmaceuticals Incorporated:

  • Vertex Pharmaceuticals has a strong market capitalization of $106.38 billion, indicating stability and potential for growth.
  • The company's stock price has shown resilience, with a 12-month high of $448.40, suggesting positive investor sentiment.
  • Vertex Pharmaceuticals has a low debt-to-equity ratio of 0.02, signifying a healthy financial structure.
  • Institutional investors like iA Global Asset Management Inc. and Capital World Investors have been increasing their holdings in the company, reflecting confidence in its future prospects.
  • The company's PEG ratio of 2.31 indicates a reasonable valuation compared to its expected earnings growth, making it an attractive investment opportunity.

Cons

Investors should be bearish about investing in Vertex Pharmaceuticals Incorporated for these reasons:

  • Vertex Pharmaceuticals' stock has a beta of 0.35, suggesting lower volatility compared to the market, which may limit potential returns for risk-seeking investors.
  • Chairman Jeffrey M. Leiden recently sold a significant number of shares, which could raise concerns about insider sentiment or future company performance.
  • While the company has shown growth, there may be increased competition and regulatory challenges in the pharmaceutical industry that could impact future earnings.
  • Some institutional investors have been reducing their positions in Vertex Pharmaceuticals, which could indicate a shift in market sentiment or concerns about the company's outlook.
  • Investors should carefully consider the company's 50-day and 200-day simple moving averages, currently at $424.83 and $384.08 respectively, to assess short-term and long-term price trends.

VRTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Vertex Pharmaceuticals stock right now?

22 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last year. There are currently 3 sell ratings, 7 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" VRTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VRTX, but not buy additional shares or sell existing shares.
View VRTX analyst ratings
or view top-rated stocks.

What is Vertex Pharmaceuticals' stock price target for 2024?

22 Wall Street research analysts have issued 1 year price objectives for Vertex Pharmaceuticals' stock. Their VRTX share price targets range from $325.00 to $540.00. On average, they expect the company's share price to reach $417.27 in the next twelve months. This suggests that the stock has a possible downside of 0.6%.
View analysts price targets for VRTX
or view top-rated stocks among Wall Street analysts.

How have VRTX shares performed in 2024?

Vertex Pharmaceuticals' stock was trading at $406.89 at the beginning of 2024. Since then, VRTX shares have increased by 3.2% and is now trading at $419.78.
View the best growth stocks for 2024 here
.

When is Vertex Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024.
View our VRTX earnings forecast
.

How were Vertex Pharmaceuticals' earnings last quarter?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced its earnings results on Monday, February, 5th. The pharmaceutical company reported $4.20 EPS for the quarter, beating the consensus estimate of $3.85 by $0.35. The pharmaceutical company earned $2.52 billion during the quarter, compared to analysts' expectations of $2.50 billion. Vertex Pharmaceuticals had a net margin of 36.68% and a trailing twelve-month return on equity of 21.91%. During the same period in the prior year, the company posted $3.33 earnings per share.
Read the conference call transcript
.

What guidance has Vertex Pharmaceuticals issued on next quarter's earnings?

Vertex Pharmaceuticals updated its FY 2024 earnings guidance on Monday, February, 5th. The company provided EPS guidance of for the period. The company issued revenue guidance of $10.6 billion-$10.8 billion, compared to the consensus revenue estimate of $10.6 billion.

What is Reshma Kewalramani's approval rating as Vertex Pharmaceuticals' CEO?

31 employees have rated Vertex Pharmaceuticals Chief Executive Officer Reshma Kewalramani on Glassdoor.com. Reshma Kewalramani has an approval rating of 76% among the company's employees.

What other stocks do shareholders of Vertex Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vertex Pharmaceuticals investors own include NVIDIA (NVDA), Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), Salesforce (CRM), Netflix (NFLX), Intel (INTC) and PayPal (PYPL).

Who are Vertex Pharmaceuticals' major shareholders?

Vertex Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.65%), Vanguard Group Inc. (8.63%), Capital World Investors (8.46%), Price T Rowe Associates Inc. MD (2.28%), Wellington Management Group LLP (2.02%) and Jennison Associates LLC (1.53%). Insiders that own company stock include Amit Sachdev, Bastiano Sanna, Bruce I Sachs, Carmen Bozic, Charles F Wagner Jr, David Altshuler, Jeffrey M Leiden, Jonathan Biller, Joy Liu, Kristen Ambrose, Lloyd Carney, Margaret G Mcglynn, Ourania Tatsis, Reshma Kewalramani, Sangeeta N Bhatia, Sangeeta N Bhatia, Stuart A Arbuckle and Yuchun Lee.
View institutional ownership trends
.

How do I buy shares of Vertex Pharmaceuticals?

Shares of VRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Vertex Pharmaceuticals have any subsidiaries?
The following companies are subsidiares of Vertex Pharmaceuticals: Aurora Biosciences Corporation, Exonics Therapeutics, Semma Therapeutics, The Vertex Foundation Inc., Torreyana Insurance Company Inc., V2X, Vertex Farmaceutica do Brasil LTDA, Vertex Holdings Inc., Vertex Pharmaceuticals (Australia) Pty. Ltd., Vertex Pharmaceuticals (CH) GmbH, Vertex Pharmaceuticals (Canada) Incorporated, Vertex Pharmaceuticals (Cayman 509) Limited, Vertex Pharmaceuticals (Cayman 765) Limited, Vertex Pharmaceuticals (Cayman 787) Limited, Vertex Pharmaceuticals (Cayman III) Limited, Vertex Pharmaceuticals (Cayman) Limited, Vertex Pharmaceuticals (Czech Republic) s.r.o, Vertex Pharmaceuticals (Delaware) LLC, Vertex Pharmaceuticals (Distribution) Incorporated, Vertex Pharmaceuticals (Europe) Limited, Vertex Pharmaceuticals (France) SAS, Vertex Pharmaceuticals (Germany) GmbH, Vertex Pharmaceuticals (Ireland) Limited, Vertex Pharmaceuticals (Italy) S.r.L., Vertex Pharmaceuticals (Netherlands) B.V., Vertex Pharmaceuticals (Poland) sp. z.o.o, Vertex Pharmaceuticals (Portugal), Vertex Pharmaceuticals (Puerto Rico) LLC, Vertex Pharmaceuticals (San Diego) LLC, Vertex Pharmaceuticals (Singapore) Pte. Ltd., Vertex Pharmaceuticals (Spain) S.L., Vertex Pharmaceuticals (Sweden) AB, Vertex Pharmaceuticals (U.K.) Limited, Vertex Pharmaceuticals GmbH, Vertex Pharmaceuticals Single Member Societe Anonyme, and Vertex Securities Corporation.
Read More
This page (NASDAQ:VRTX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners